EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications

Yoko Kobayashi Takahashi iD, Kenshiro Tabata, Shimpei Baba iD, Eri Takeshita, Noriko Sumitomo, Yuko Shimizu-Motohashi, Takashi Saito iD, Eiji Nakagawa, Atsushi Ishii, Shinichi Hirose iD, Mitsuhiro Kato, Naomichi Matsumoto iD und 2 weitere

Epilepsia Open · 2025

DOI: 10.1002/epi4.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Yoko Kobayashi Takahashi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Epilepsies, Myoclonic, Gain of Function Mutation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation, National Center of Neurology and Psychiatry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A large number of cases with Dravet syndrome (DS) has been attributed to SCN1A loss of function (LOF), whereas SCN1A gain‐of‐function (GOF) causes early infantile developmental and epileptic encephalopathy (EIDEE) and familial hemiplegic migraine 3. We retrospectively analyzed 37 individuals with SCN1A pathogenic variants at our institute between January 2012 and October 2024 to investigate phenotype–function correlations. Variant functions were classified as LOF, GOF, or mixed, based on existing patch‐clamp data, paralog sodium channel experimental findings, and in silico prediction tools. Clinical characteristics, antiseizure medication (ASM) responses, and variant location were compared. Nine variants were novel. One variant with insufficient data for functional prediction was excluded. Of the 36 cases with predictable functions, five cases (14%) were classified as GOF/mixed (DS = 4, EIDEE = 1) and 31 (86%) as LOF (DS = 31). GOF/mixed‐DS had earlier epilepsy onset but otherwise resembled LOF‐DS. Sodium channel blocking ASMs (SCB‐ASMs) did not exacerbate seizures in GOF/mixed DS cases, with carbamazepine reducing seizures in one case. GOF/mixed variants clustered in the intracellular S6 segment, whereas LOF variants clustered in the S5–S6 pore loop. These findings highlight a potential GOF effect for certain DS cases, suggesting that SCB‐ASMs may be effective for GOF/mixed DS. This underscores the importance of functional characterization for tailored therapy, warranting further research to confirm and extend these results. Plain Language Summary Dravet syndrome is a severe epilepsy that usually begins in infancy and is linked to changes in a gene called SCN1A . Most cases are caused by gene changes that reduce function, but in some cases, the gene may become overactive. In this study, we found that some patients with Dravet syndrome had these overactive changes and still showed typical symptoms. We found that people with overactive SCN1A function might respond differently to certain medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.1 Voltage-Gated Sodium ChannelEpilepsies, MyoclonicGain of Function MutationHumansMaleFemalePhenotypeChildChild, PreschoolAnticonvulsantsRetrospective StudiesAdolescentInfantAdultYoung Adult

Stichwörter der Autor:innen

Dravet syndromeSCN1Aepilepsyepileptic encephalopathygain of functionsodium channel

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, humanAnticonvulsants

Autor:innen und Institutionen

  • Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Department of Neurology, University of Arizona, Tucson, Arizona, USA.
  • General Medical Research Center, School of Medicine, Fukuoka University, Fukuoka, Japan.
  • Department of Pediatrics, Showa Medical University School of Medicine, Tokyo, Japan.
  • Epilepsy Medical Center, Showa Medical University Hospital, Tokyo, Japan.

ORCID-Profile: Yoko Kobayashi Takahashi, Shimpei Baba, Takashi Saito, Shinichi Hirose, Naomichi Matsumoto, Ken Inoue

Förderung

  • Japan Society for the Promotion of Science
  • Takeda Science Foundation
  • National Center of Neurology and Psychiatry
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kobayashi Takahashi, Y., Tabata, K., Baba, S., Takeshita, E., Sumitomo, N., Shimizu-Motohashi, Y., Saito, T., Nakagawa, E., Ishii, A., Hirose, S., Kato, M., Matsumoto, N., Komaki, H., & Inoue, K. (2025). SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications. Epilepsia Open. https://doi.org/10.1002/epi4.70080

Vancouver

Kobayashi Takahashi Y, Tabata K, Baba S, Takeshita E, Sumitomo N, Shimizu-Motohashi Y, et al. SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications. Epilepsia Open. 2025. doi:10.1002/epi4.70080

BibTeX
@article{KobayashiTakahashi2025,
  author = {Kobayashi Takahashi, Yoko and Tabata, Kenshiro and Baba, Shimpei and Takeshita, Eri and Sumitomo, Noriko and Shimizu-Motohashi, Yuko and Saito, Takashi and Nakagawa, Eiji and Ishii, Atsushi and Hirose, Shinichi and Kato, Mitsuhiro and Matsumoto, Naomichi and Komaki, Hirofumi and Inoue, Ken},
  title = {SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70080}
}
Kostenlos starten →